Aciclovir Versus Placebo for HSV-2 Meningitis — AMEN

Herpes Simplex 2 Clinical Trial

Official title:
Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)

Status Not yet recruiting

Clinical Trial Summary

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05452928
Study type	Interventional
Source	Aalborg University Hospital
Contact	Jacob Bodilsen, MD
Phone	004597663920
Email	jacob.bodilsen@rn.dk
Status	Not yet recruiting
Phase	Phase 4
Start date	January 1, 2024
Completion date	June 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04664127` - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Active, not recruiting	`NCT03282916` - Anti-viral Therapy in Alzheimer's Disease	Phase 2
Active, not recruiting	`NCT04710030` - Valacyclovir for Mild Cognitive Impairment	Phase 2
Completed	`NCT01681420` - Improving Blood Safety and HIV Testing in Brazil	N/A
Recruiting	`NCT05823779` - A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects